论文部分内容阅读
目的:对新序贯疗法、三联疗法治疗幽门螺杆菌阳性萎缩性胃炎的临床治疗效果探讨和分析。方法:选取我院在2014年1月至2016年12月期间接受治疗的幽门螺杆菌阳性萎缩性胃炎患者60例为本次的研究对象,将其按照随机数字表法分为对照组与研究组,每组各有30例。对照组患者采用三联疗法进行治疗,研究组患者采用新序贯疗法进行治疗,将两组患者在分别进行不同治疗后的治疗效果进行对比分析。结果:研究组患者治疗的总有效率为92.3%,对照组患者治疗的总有效率为70.16%,研究组的总有效率明显的高于对照组,两组间相比,P<0.05,差异具有统计学意义。研究组患者的不良反应发生率也明显的低于对照组患者,两组间相比有明显差异,P<0.05,差异具有统计学意义。结论:新序贯疗法治疗幽门螺杆菌阳性萎缩性胃炎可以得到确切有效的临床治疗效果,对患者的症状及病理有明显的改善作用,患者在治疗后的不良反应发生率也相对较低,值得在临床上推广应用。
Objective: To investigate and analyze the clinical effect of new sequential therapy and triple therapy on Helicobacter pylori positive atrophic gastritis. Methods: Sixty patients with Helicobacter pylori-positive atrophic gastritis who were treated in our hospital from January 2014 to December 2016 were selected as the study subjects and divided into control group and study group according to random number table , Each group has 30 cases. Patients in the control group were treated with triple therapy, and patients in the study group were treated with new sequential therapy. The therapeutic effects of the two groups of patients after different treatments were compared and analyzed. Results: The total effective rate was 92.3% in the study group and 70.16% in the control group. The total effective rate in the study group was significantly higher than that in the control group, P <0.05, the difference was significant has statistical significane. The incidence of adverse reactions in the study group was also significantly lower than that in the control group, with significant difference between the two groups (P <0.05). The difference was statistically significant. Conclusion: The new sequential therapy for Helicobacter pylori-positive atrophic gastritis can get effective and effective clinical treatment effect, which has a significant improvement on the symptoms and pathology of patients, and the incidence of adverse reactions in patients after treatment is relatively low, which is worth Promote the clinical application.